{"filings":[{"id":1839797,"accession_number":"0001638833-26-000069","cik":1638833,"company_name":"Surgery Partners, Inc.","ticker":"SGRY","form_type":"8-K","filed_at":"2026-07-24T13:01:47+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Surgery Partners to sell Idaho Falls hospitals to Intermountain Health for ~$795M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Transaction values combined facilities at ~$1.15B; Surgery Partners receives ~$795M in total consideration.","Sale includes Mountain View Hospital and Idaho Falls Community Hospital; physician ownership of MVH unchanged.","Closing subject to physician approvals, HSR waiting period, and other regulatory consents; expected in coming months.","Company reaffirms 2026 revenue guidance of $3.35B-$3.45B and Adjusted EBITDA of at least $530M, excluding transaction.","Q2 2026 earnings release scheduled for August 10, 2026, before market open."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1759100722.2663202,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":"2026-07-24","daily_digest_url":"/daily/2026-07-24","daily_digest_rank":7},{"id":889996,"accession_number":"0001638833-26-000050","cik":1638833,"company_name":"Surgery Partners, Inc.","ticker":"SGRY","form_type":"8-K","filed_at":"2026-06-05T20:50:44+00:00","items":["5.07"],"status":"ready","headline":"Surgery Partners annual meeting: all director nominees re-elected, say-on-pay and auditor ratified","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Class II directors Devin O'Reilly, Brent Turner, and Laura L. Forese re-elected with >90M votes for each.","Advisory vote on executive compensation approved: 111.6M for, 2.0M against, 15K abstentions.","Ratification of Ernst & Young as independent auditor for FY 2026 approved: 119.8M for, 62.9K against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1759100722.2663202,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94304,"accession_number":"0001638833-26-000044","cik":1638833,"company_name":"Surgery Partners, Inc.","ticker":"SGRY","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Surgery Partners Q1 revenue $810.9M (+4.5%), net loss $35.9M; reaffirms FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $810.9M (+4.5% YoY); same-facility revenue +4.4% on 0.6% case growth and 3.8% revenue per case.","Net loss attributable to Surgery Partners $35.9M; Adjusted EBITDA $102.3M vs $103.9M YoY.","Full-year 2026 guidance reaffirmed: revenue $3.35-3.45B, Adj. EBITDA at least $530M.","Cash and equivalents $182.3M; revolver capacity $666.1M; net debt/EBITDA ratio 4.3x.","Operating cash flow $11.7M in Q1 vs $6.0M YoY on working capital timing."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":810900000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1759100722.2663202,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106554,"accession_number":"0001638833-26-000006","cik":1638833,"company_name":"Surgery Partners, Inc.","ticker":"SGRY","form_type":"8-K","filed_at":"2026-03-02T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Surgery Partners Q4 rev $885M (+2.4%), Adj. EBITDA $156.9M (-4.2%), net loss $15M, 2026 guidance, $200M buyback","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $885.0M (+2.4% YoY); full-year $3.3B (+6.2%). Same-facility revenue +3.5% Q4.","Adj. EBITDA $156.9M (-4.2% YoY); full-year $526.2M (+3.5%). Net loss $15.0M Q4, $77.9M FY.","2026 guidance: Adj. EBITDA at least $530M; revenue range $3.35B-$3.45B.","Board authorized $200M share repurchase program on February 26, 2026.","Operating cash flow $103.4M Q4 (down from $111.4M); net debt/EBITDA ~4.3x."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1759100722.2663202,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122894,"accession_number":"0001104659-25-121563","cik":1638833,"company_name":"Surgery Partners, Inc.","ticker":"SGRY","form_type":"8-K","filed_at":"2025-12-16T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Surgery Partners subsidiary issues additional $425M of 7.25% Senior Notes due 2032","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Surgery Center Holdings issued $425M add-on to existing 7.250% Senior Notes due 2032; total now $1.225B.","Notes are fungible with $800M series issued April 2024 under same CUSIP (Reg S separate for 40 days).","Issued under Third Supplemental Indenture with Wilmington Trust, National Association as trustee.","Use of proceeds not disclosed in the filing.","Notes rank equally with existing unsecured obligations of the issuer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1759100722.2663202,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122893,"accession_number":"0001104659-25-120386","cik":1638833,"company_name":"Surgery Partners, Inc.","ticker":"SGRY","form_type":"8-K","filed_at":"2025-12-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Surgery Partners subsidiary prices $425M add-on of 7.250% senior notes due 2032","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issuer Surgery Center Holdings priced $425M aggregate principal of 7.250% senior unsecured notes due 2032.","Notes are part of same series as $800M notes originally issued in April 2024.","Net proceeds to be used for general corporate purposes, including repaying revolving credit facility.","Offering expected to close on December 16, 2025, subject to customary conditions.","Notes guaranteed on senior unsecured basis by domestic wholly-owned subsidiaries that guarantee senior secured credit facilities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1759100722.2663202,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122892,"accession_number":"0001104659-25-120159","cik":1638833,"company_name":"Surgery Partners, Inc.","ticker":"SGRY","form_type":"8-K","filed_at":"2025-12-11T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Surgery Partners subsidiary to offer $425M add-on 7.250% senior notes due 2032","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Intent to offer $425M additional 7.250% Senior Notes due 2032, same series as April 2024 issuance.","Net proceeds used for general corporate purposes, including repaying revolver borrowings.","Notes guaranteed on senior unsecured basis by domestic subsidiaries that guarantee credit facilities.","Offering conducted under Rule 144A and Regulation S; notes not registered under Securities Act."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1759100722.2663202,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122891,"accession_number":"0001638833-25-000166","cik":1638833,"company_name":"Surgery Partners, Inc.","ticker":"SGRY","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Surgery Partners appoints Justin Oppenheimer as COO and National Group President effective Jan 1, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Oppenheimer joins from Hospital for Special Surgery, where he was Chief Strategy Officer and COO.","Base salary of $660,000, signing bonus of $500,000 (subject to repayment if resigns within 1 year).","Eligible for annual bonus target of 100% of base salary; annual equity target of $1.5M.","Initial equity grant of $1.25M in restricted stock vesting on first anniversary.","Reports to CEO; severance includes 12 months base salary plus benefits for without-cause termination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1759100722.2663202,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122890,"accession_number":"0001638833-25-000159","cik":1638833,"company_name":"Surgery Partners, Inc.","ticker":"SGRY","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Surgery Partners Q3 revenue up 6.6% to $821.5M, net loss $22.7M; FY guidance cut","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $821.5M (+6.6% YoY); same-facility revenue +6.3%, cases +3.4%.","Net loss attributable to SGRY of $22.7M; Adjusted EBITDA $136.4M (+6.1% YoY).","Full-year 2025 guidance: revenue $3.275-3.30B, Adjusted EBITDA $535-540M (revised down).","Leverage ratio 4.2x net debt/EBITDA; Q3 operating cash flow $83.6M vs $65.2M YoY.","Management cites softer volume, payor mix, and delayed capital deployment for guidance revision."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":2423700000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1759100722.2663202,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139591,"accession_number":"0001638833-25-000153","cik":1638833,"company_name":"Surgery Partners, Inc.","ticker":"SGRY","form_type":"8-K","filed_at":"2025-09-16T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Surgery Partners' National Group President Harrison R. Bane resigns effective Oct 3, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Harrison R. Bane, National Group President, resigns effective October 3, 2025.","Resignation is not due to any disagreement with the company on operations, policies, or practices.","No successor has been announced at this time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1759100722.2663202,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139590,"accession_number":"0001104659-25-077656","cik":1638833,"company_name":"Surgery Partners, Inc.","ticker":"SGRY","form_type":"8-K","filed_at":"2025-08-13T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Surgery Partners closes $1.383B term loan refinancing; extends maturities to 2030/2028","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["New $1.383B 2025 Refinancing Term Loans replace existing term loans; maturity extended to Dec 19, 2030.","Revolving credit commitments refinanced; new 2025 Refinancing Revolving Loans mature Dec 19, 2028.","Interest rate: Term SOFR + 2.50% or alternate base rate + 1.50%.","Term loans amortize in equal quarterly installments of 0.25% of original principal starting Q3 2025.","Voluntary prepayment permitted with 1% call premium for repricing events within first 6 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1759100722.2663202,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139589,"accession_number":"0001638833-25-000138","cik":1638833,"company_name":"Surgery Partners, Inc.","ticker":"SGRY","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Surgery Partners Chairman Wayne DeVeydt resigns; Blair Hendrix named new Chairman","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Wayne S. DeVeydt resigned as director and Executive Chairman effective August 4, 2025.","Resignation not due to any disagreement with the company on operations, policies, or practices.","Board appointed Blair E. Hendrix as Chairman of the Board effective immediately.","Board reduced size from 11 to 10 directors concurrent with resignation.","No replacement for the vacant board seat announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1759100722.2663202,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139588,"accession_number":"0001638833-25-000132","cik":1638833,"company_name":"Surgery Partners, Inc.","ticker":"SGRY","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Surgery Partners Q2 revenue up 8.4% to $826.2M; Adj EBITDA $129M, up 9%; reaffirms FY2025 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $826.2M (+8.4% YoY); same-facility revenue +5.1%, same-facility cases +3.4%.","Adjusted EBITDA $129.0M (+9.0% YoY); net loss attributable to Surgery Partners $2.5M.","Full-year 2025 guidance reaffirmed: revenue $3.30-3.45B, Adjusted EBITDA $555-565M.","Cash $250.1M and $394.9M revolver capacity at June 30, 2025; net debt/EBITDA 4.1x.","CEO cites active evaluation of portfolio optimization to reduce leverage and accelerate cash flow."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":1602200000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1759100722.2663202,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157170,"accession_number":"0001638833-25-000117","cik":1638833,"company_name":"Surgery Partners, Inc.","ticker":"SGRY","form_type":"8-K","filed_at":"2025-06-17T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Surgery Partners ends Bain Capital buyout talks; reaffirms 2025 guidance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Special Committee determined that remaining independent provides greater long-term value than Bain Capital's acquisition proposal.","Company reaffirms 2025 revenue guidance of $3.30B-$3.45B and Adjusted EBITDA of $555M-$565M.","Surgery Partners plans to host an Investor Day in H2 2025 to detail growth strategy.","Bain Capital remains a long-term investor and collaborator despite no deal."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1759100722.2663202,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157169,"accession_number":"0001638833-25-000096","cik":1638833,"company_name":"Surgery Partners, Inc.","ticker":"SGRY","form_type":"8-K","filed_at":"2025-06-06T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Surgery Partners shareholders re-elect three directors and approve 2025 incentive plan at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders re-elected John A. Deane, Teresa DeLuca, M.D., and Wayne S. DeVeydt as Class I directors for three-year terms.","Advisory vote on executive compensation approved with ~96.6M votes for and ~19.2M against.","2025 Omnibus Incentive Plan approved with ~101.7M votes for, ~14.0M against.","Ratification of Ernst & Young as independent auditor for FY2025 passed with ~122.1M votes for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":1759100722.2663202,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157168,"accession_number":"0001638833-25-000089","cik":1638833,"company_name":"Surgery Partners, Inc.","ticker":"SGRY","form_type":"8-K","filed_at":"2025-05-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Surgery Partners Q1 revenue up 8.2% to $776M; Adj EBITDA $103.9M (+6.6%); net loss $37.7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Same-facility revenue +5.2%, same-facility cases +6.5% YoY; revenue per case -1.2%.","Net loss attributable to Surgery Partners $37.7M; no GAAP EPS provided.","Adjusted EBITDA $103.9M vs. $97.5M in prior-year quarter (+6.6%).","Full-year 2025 guidance reaffirmed: revenue $3.30-$3.45B, Adj EBITDA $555-$565M.","Cash $229.3M + $388.9M revolver capacity; net debt/EBITDA ~4.1x; operating cash flow $6.0M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":776000000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1759100722.2663202,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175519,"accession_number":"0001638833-25-000031","cik":1638833,"company_name":"Surgery Partners, Inc.","ticker":"SGRY","form_type":"8-K","filed_at":"2025-03-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Surgery Partners Q4 revenue up 17.5% to $864.4M; Adj EBITDA +15.1%; sets 2025 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $864.4M (+17.5% YoY); full-year revenue $3.1B (+13.5% YoY).","Q4 adjusted EBITDA $163.8M (+15.1%); full-year $508.2M (+16.0%).","Same-facility revenue growth 5.6% in Q4, 8.0% full year; cases +5.1% and +3.9% respectively.","Net loss attributable $108.5M Q4, $168.1M full year; includes non-cash tax valuation allowance. No federal income taxes expected until 2029.","2025 guidance: revenue $3.30-$3.45B; Adj EBITDA $555-$565M. Liquidity >$770M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1759100722.2663202,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175518,"accession_number":"0001104659-25-006658","cik":1638833,"company_name":"Surgery Partners, Inc.","ticker":"SGRY","form_type":"8-K","filed_at":"2025-01-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Surgery Partners receives $25.75/share buyout proposal from Bain Capital; Bain owns ~39%","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Bain Capital proposes to acquire all outstanding shares not already owned for $25.75 per share in cash.","Bain Capital and affiliates own approximately 39% of Surgery Partners' outstanding common stock.","A Special Committee of independent directors will evaluate the proposal with advisors.","Any transaction subject to non-waivable condition requiring majority approval of shares not owned by Bain.","Proposal is non-binding; no assurance that a definitive agreement will be reached."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1759100722.2663202,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175517,"accession_number":"0001638833-25-000002","cik":1638833,"company_name":"Surgery Partners, Inc.","ticker":"SGRY","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Surgery Partners appoints Dr. Laura L. Forese to Board of Directors, effective Jan 10, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Forese, former EVP and COO of New York-Presbyterian, appointed as independent director.","Board size increases to 11 members; she fills a Class II vacancy, term expires at 2026 annual meeting.","She will serve on the Compliance and Ethics Committee; compensation consistent with other non-employee directors.","Dr. Forese is an orthopedic surgeon with over 40 years of healthcare administration experience."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":1759100722.2663202,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192473,"accession_number":"0001638833-24-000143","cik":1638833,"company_name":"Surgery Partners, Inc.","ticker":"SGRY","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Surgery Partners Q3 revenue $770.4M (+14.3% YoY); adjusted EBITDA $128.6M (+21.9%)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $770.4M, +14.3% YoY; same-facility revenue +4.2% on 3.7% case growth.","Adjusted EBITDA $128.6M, +21.9% YoY; margin 16.7%, expanding 100 bps.","Net loss attributable to Surgery Partners was $31.7M.","FY 2024 outlook reaffirmed: revenue >$3.075B, adjusted EBITDA >$508M.","Cash $221.8M, revolver capacity $595.8M; total net debt/EBITDA 3.8x."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.47,"consensus_revenue_estimate":null,"consensus_revenue_actual":2249900000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1759100722.2663202,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208941,"accession_number":"0001638833-24-000137","cik":1638833,"company_name":"Surgery Partners, Inc.","ticker":"SGRY","form_type":"8-K","filed_at":"2024-08-23T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Surgery Partners dismisses Deloitte, engages EY as auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Deloitte & Touche dismissed as independent auditor effective Aug 21, 2024; no adverse opinions or disagreements.","Ernst & Young appointed as new independent registered public accounting firm for fiscal year ending Dec 31, 2024.","No reportable events or disagreements with Deloitte during fiscal 2022-2023 and subsequent interim period.","Deloitte provided letter agreeing with company's statements, filed as Exhibit 16."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1759100722.2663202,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208940,"accession_number":"0001638833-24-000132","cik":1638833,"company_name":"Surgery Partners, Inc.","ticker":"SGRY","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Surgery Partners Q2 revenue +14.2% to $762.1M; raises FY2024 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $762.1M (+14.2% YoY); same-facility revenue up 9.9%, cases up 3.9%.","Adjusted EBITDA $118.3M (+18.1%); margin 15.5% (+50 bps).","Net loss attributable to company $15.5M.","FY2024 guidance raised: revenue >$3.075B, Adjusted EBITDA >$508M.","Deployed ~$220M on acquisitions YTD; balance sheet refinanced and hedged."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":1479500000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1759100722.2663202,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226763,"accession_number":"0001104659-24-073419","cik":1638833,"company_name":"Surgery Partners, Inc.","ticker":"SGRY","form_type":"8-K","filed_at":"2024-06-20T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Surgery Partners closes $1.4B term loan refinancing, extending maturity to 2030","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$1.4B aggregate principal of 2024 Refinancing Term Loans priced at Term SOFR + 2.75% or base rate + 1.75%.","New loans mature December 19, 2030 and replace all existing term loans under the credit agreement.","Amortization: equal quarterly installments of 0.25% of original principal, starting Q3 2024.","Voluntary prepayments subject to 1% call premium if made within 6 months due to a repricing event."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1759100722.2663202,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226762,"accession_number":"0001638833-24-000127","cik":1638833,"company_name":"Surgery Partners, Inc.","ticker":"SGRY","form_type":"8-K","filed_at":"2024-06-11T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Surgery Partners shareholders approve all four proposals at 2024 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Re-elected Class III directors Clifford Adlerz, J. Eric Evans, Blair Hendrix, and Andrew Kaplan.","Advisory vote on executive compensation passed with ~121.2M for, ~1.1M against.","Employee stock purchase plan approved (~122.2M for); plan qualified under Section 423.","Appointment of Deloitte & Touche as 2024 auditor ratified (~124.2M for)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":1759100722.2663202,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226761,"accession_number":"0001638833-24-000110","cik":1638833,"company_name":"Surgery Partners, Inc.","ticker":"SGRY","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Surgery Partners Q1 revenue up 7.7% to $717.4M, Adjusted EBITDA $97.5M; raises FY outlook","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $12.4M; Adjusted EBITDA $97.5M (+8.2% YoY); margin 13.6%.","Same-facility revenue +10.2% YoY with 8.8% revenue per case increase and 1.3% case growth.","FY 2024 guidance raised: revenue at least $3.05B, Adjusted EBITDA at least $505M.","Completed refinancing of term loan and unsecured notes; no material debt maturities until 2030.","Cash $185.2M; revolver capacity $607.3M; net debt/EBITDA ratio ~3.5x."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":717400000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1759100722.2663202,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226760,"accession_number":"0001104659-24-045863","cik":1638833,"company_name":"Surgery Partners, Inc.","ticker":"SGRY","form_type":"8-K","filed_at":"2024-04-10T23:59:59+00:00","items":["1.01","1.02","2.03","9.01"],"status":"ready","headline":"Surgery Partners issues $800M 7.250% notes due 2032, refinances higher-coupon debt","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Subsidiary Surgery Center Holdings issued $800M aggregate principal of 7.250% senior unsecured notes due April 15, 2032.","Proceeds used to redeem existing 10.000% Senior Notes due 2027 and 6.750% Senior Notes due 2025 at par plus accrued interest.","Redemption date is April 25, 2024; existing indentures satisfied and discharged.","Interest on new notes payable semi-annually on April 15 and October 15, beginning October 15, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1759100722.2663202,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245727,"accession_number":"0001638833-24-000081","cik":1638833,"company_name":"Surgery Partners, Inc.","ticker":"SGRY","form_type":"8-K","filed_at":"2024-03-26T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Surgery Partners prices $800M 7.250% senior notes due 2032 to refinance existing debt","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issuer (Surgery Center Holdings) priced $800M aggregate principal of 7.250% senior unsecured notes due 2032.","Net proceeds to redeem all outstanding 6.750% notes due 2025 and 10.000% notes due 2027.","Expected close on April 10, 2024, subject to customary conditions.","Excess proceeds will be used for general corporate purposes, including future acquisitions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1759100722.2663202,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245726,"accession_number":"0001638833-24-000079","cik":1638833,"company_name":"Surgery Partners, Inc.","ticker":"SGRY","form_type":"8-K","filed_at":"2024-03-26T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Surgery Partners subsidiary plans $600M senior notes offering due 2032 to refinance higher-coupon debt","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$600M aggregate principal of senior unsecured notes due 2032; interest rate set at pricing.","Proceeds to redeem outstanding 6.750% notes due July 2025 and 10.000% notes due April 2027.","Excess proceeds for general corporate purposes, including funding future acquisitions.","Notes offered under Rule 144A/Reg S; not registered under Securities Act.","Guarantees from domestic subsidiaries that also guarantee senior secured credit facilities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1759100722.2663202,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245725,"accession_number":"0001638833-24-000026","cik":1638833,"company_name":"Surgery Partners, Inc.","ticker":"SGRY","form_type":"8-K","filed_at":"2024-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Surgery Partners Q4 revenue +4% to $735.4M; FY Adjusted EBITDA $438.1M; guides 2024 revenue >$3B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $735.4M (+4.0% YoY); full-year revenue $2.74B (+8.0% YoY).","Q4 Adjusted EBITDA $142.3M (+17.8% YoY); FY Adjusted EBITDA $438.1M (+15.2% YoY).","Days adjusted same-facility revenue +8.1% Q4, +11.3% full year vs 2022.","Net loss attributable to common: $1.0M Q4, $11.9M full year 2023.","2024 guidance: revenue >$3.0B, Adjusted EBITDA >$495M; liquidity ~$900M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":2743300000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1759100722.2663202,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245724,"accession_number":"0001638833-24-000006","cik":1638833,"company_name":"Surgery Partners, Inc.","ticker":"SGRY","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["2.02"],"status":"ready","headline":"Surgery Partners reaffirms 2023 guidance, projects 2024 Adj. EBITDA >$495M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Reaffirmed 2023 Adjusted EBITDA guidance of $436M-$440M; revenue ~$2.75B.","Projected 2024 Adjusted EBITDA greater than $495 million, implying ~13% YoY growth.","Guidance based on results through November 2023, subject to year-end adjustments.","Company updated investors at J.P. Morgan Healthcare Conference on January 8, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":2743300000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1759100722.2663202,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263190,"accession_number":"0001104659-23-127412","cik":1638833,"company_name":"Surgery Partners, Inc.","ticker":"SGRY","form_type":"8-K","filed_at":"2023-12-20T23:59:59+00:00","items":["1.01","1.02","2.03","9.01"],"status":"ready","headline":"Surgery Partners enters $1.4B term loan and $703.75M revolver, refinances existing debt","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["New $1.4B senior secured term loan due 2030 and $703.75M revolving credit facility due 2028.","Term loan bears interest at Term SOFR + 3.50%; revolving loans at Term SOFR + 3.25%.","Proceeds used to fully repay existing $1.4B term loan due 2026 and revolver, pay fees, and general corporate.","Term loan amortizes at 0.25% per quarter starting June 2024; mandatory prepayment triggers apply.","Facilities guaranteed by Holdings and domestic subsidiaries, secured by substantially all assets."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1759100722.2663202,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263189,"accession_number":"0001104659-23-126907","cik":1638833,"company_name":"Surgery Partners, Inc.","ticker":"SGRY","form_type":"8-K","filed_at":"2023-12-18T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Surgery Partners selling stockholders offer 8M shares at $33.44; company receives no proceeds","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Selling stockholders offering 8,000,000 shares of common stock at $33.44 per share via underwritten offering.","Company receives no proceeds from the sale; all shares sold by existing stockholders.","Underwriting agreement with Jefferies LLC; closing expected on or about December 19, 2023.","Offering made under existing automatic shelf registration statement (333-252399)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1759100722.2663202,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263188,"accession_number":"0001638833-23-000102","cik":1638833,"company_name":"Surgery Partners, Inc.","ticker":"SGRY","form_type":"8-K","filed_at":"2023-12-06T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Surgery Partners subsidiary receives commitments for $1.4B new term loan; refinances 2026 debt","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["New $1.4B senior secured term loan at SOFR+3.50%, maturing 7 years after closing.","Also expects $703.75M revolving credit facility (refinanced and increased), maturing 5 years after closing.","Proceeds to repay existing term loan due 2026 and fund transaction fees & expenses.","CFO cites more favorable terms, extended maturity, lower interest costs, and increased liquidity.","Closing expected in December 2023, subject to customary conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1759100722.2663202,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263187,"accession_number":"0001638833-23-000093","cik":1638833,"company_name":"Surgery Partners, Inc.","ticker":"SGRY","form_type":"8-K","filed_at":"2023-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Surgery Partners Q3 revenue up 8.6% to $674M; raises FY Adjusted EBITDA guidance to $436-440M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenues $674.1M (+8.6% YoY); net loss improved to $4.9M from $25M.","Adjusted EBITDA $105.5M (+9.7% YoY); margin improved to 15.7%.","Same-facility revenues up 14.2% (days adjusted); case volume +2.9%, revenue per case +11.0%.","Full-year 2023 Adjusted EBITDA guidance raised to $436-440M; revenue ~$2.75B.","Free Cash Flow of $63.2M in Q3; cash and revolver availability $781M total."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":2007900000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1759100722.2663202,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280390,"accession_number":"0001638833-23-000080","cik":1638833,"company_name":"Surgery Partners, Inc.","ticker":"SGRY","form_type":"8-K","filed_at":"2023-08-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Surgery Partners Q2 revenue $667.6M (+8.5% YoY), EBITDA beat; FY guidance raised","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $667.6M (+8.5% YoY); same-facility revenue +8.3% (~10% adj. for $8M cyber headwind).","Net income $18.9M vs ($18.4M) loss; Adjusted EBITDA $100.2M, +16.4% YoY; margin 15.0%.","FY 2023 Adjusted EBITDA guidance raised to >$435M; revenue reaffirmed >$2.75B; free cash flow >$140M.","Combined surgical case volume +5%; non-consolidated minority revenue +30%.","Deployed ~$60M capital in Q2; new partnership with Methodist Health System in Dallas, TX."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":1333800000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1759100722.2663202,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":298934,"accession_number":"0001638833-23-000074","cik":1638833,"company_name":"Surgery Partners, Inc.","ticker":"SGRY","form_type":"8-K","filed_at":"2023-06-07T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Surgery Partners annual meeting re-elects Class II directors, approves say-on-pay, ratifies auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Class II directors Maryland, O'Reilly, Turner re-elected with >105M votes each; broker non-votes ~1.5M.","Non-binding advisory vote on executive compensation approved: 118.1M for, 3.3M against.","Annual say-on-pay frequency chosen: 120.9M votes for one year; board adopts annual frequency.","Ratification of Deloitte & Touche as auditor for FY2023: 122.9M for, 40k against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1759100722.2663202,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":298933,"accession_number":"0001638833-23-000067","cik":1638833,"company_name":"Surgery Partners, Inc.","ticker":"SGRY","form_type":"8-K","filed_at":"2023-05-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Surgery Partners Q1 revenue up 11.7% to $666.2M, net loss $24.9M, raises 2023 EBITDA guidance >$430M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $666.2M (+11.7% YoY); same-facility revenue +10.3% (cases +5.3%, revenue per case +4.8%).","Net loss attributable to SGRY $24.9M vs net income $12.2M in Q1 2022; Adjusted EBITDA $90.1M (+17% from $77.1M).","Raises 2023 Adjusted EBITDA guidance to >$430M; Q1 free cash flow $20.5M, deployed $60M on five acquisitions.","New strategic partnerships with Intermountain Health and OhioHealth for expansion in new markets.","Net debt to EBITDA 4.3x; liquidity ~$800M ($245.5M cash + $545.9M revolver availability)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":666200000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1759100722.2663202,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319109,"accession_number":"0001638833-23-000019","cik":1638833,"company_name":"Surgery Partners, Inc.","ticker":"SGRY","form_type":"8-K","filed_at":"2023-03-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Surgery Partners Q4 revenue up 15.9% to $707.1M; sets 2023 EBITDA guidance >$425M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $707.1M in Q4 (+15.9% YoY); full-year revenue $2.5B (+14.1%).","Net loss attributable to common $23.4M in Q4; full-year net loss $54.6M.","Adjusted EBITDA $120.8M in Q4 (+5.6% YoY); full-year $380.2M (+12.0%).","Days adjusted same-facility revenue +10.7% in Q4; +7.7% for full year.","2023 guidance: revenue >$2.75B, Adjusted EBITDA >$425M; liquidity >$830M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.59,"consensus_revenue_estimate":null,"consensus_revenue_actual":2539300000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1759100722.2663202,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319108,"accession_number":"0001638833-23-000002","cik":1638833,"company_name":"Surgery Partners, Inc.","ticker":"SGRY","form_type":"8-K","filed_at":"2023-01-09T23:59:59+00:00","items":["2.02"],"status":"ready","headline":"Surgery Partners reaffirms 2022 revenue and Adj. EBITDA guidance at J.P. Morgan conference","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Reaffirms 2022 revenue guidance of $2.50B to $2.55B.","Reaffirms 2022 Adjusted EBITDA guidance of $375M to $385M.","Guidance based on results through November 2022; year-end adjustments pending.","Management presenting at 41st Annual J.P. Morgan Healthcare Conference on Jan 9, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1759100722.2663202,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":337334,"accession_number":"0001104659-22-129608","cik":1638833,"company_name":"Surgery Partners, Inc.","ticker":"SGRY","form_type":"8-K","filed_at":"2022-12-22T23:59:59+00:00","items":["3.02","8.01","9.01"],"status":"ready","headline":"Surgery Partners closes $225M private placement of common stock to Bain affiliates at $24.50/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Completed private placement of $225M common stock to affiliates of Bain Capital; issued 9,183,673 shares at $24.50/share.","Transaction closed on December 22, 2022; price matched November 21 public offering.","Amended registration rights agreement granting Bain request rights for shelf registration of the shares.","Holdings III and Holdings IV joined as parties to the registration rights agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1759100722.2663202,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":337333,"accession_number":"0001104659-22-121217","cik":1638833,"company_name":"Surgery Partners, Inc.","ticker":"SGRY","form_type":"8-K","filed_at":"2022-11-22T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Surgery Partners launches public offering of 23.5M shares at $24.50 and $225M private placement to Bain Capital","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Public offering of 23,469,388 shares at $24.50/share, with option for up to 3,520,408 additional shares.","Concurrent private placement of $225 million (9,183,673 shares at $24.50/share) to Bain Capital affiliate.","Public offering expected to close Nov 23, 2022; private placement expected within 30 days.","Private placement is exempt from registration under Section 4(a)(2) and Rule 506(b).","Shares issued to Bain Capital will be subject to restrictive legend; registration rights agreement to be amended."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1759100722.2663202,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":337332,"accession_number":"0001638833-22-000132","cik":1638833,"company_name":"Surgery Partners, Inc.","ticker":"SGRY","form_type":"8-K","filed_at":"2022-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Surgery Partners Q3 revenue +11% to $620.6M, Adj EBITDA $96.2M, reaffirms FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $620.6M (+11.0% YoY); same-facility revenue +5.1% (cases +3.3%, rev/case +1.8%).","Net loss $25.0M vs $22.9M loss; Adjusted EBITDA $96.2M (+26% YoY); margin 15.5% (+180bps).","Reaffirms FY2022 Adj EBITDA $375M-$385M; revenue $2.5-$2.55B.","YTD deployed $240M on acquisitions (12 facilities) at sub-8x EBITDA; added 150+ physicians.","Liquidity ~$500M ($154.8M cash + $342M revolver capacity); net debt/EBITDA 6.0x."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":1832200000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1759100722.2663202,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":354702,"accession_number":"0001638833-22-000120","cik":1638833,"company_name":"Surgery Partners, Inc.","ticker":"SGRY","form_type":"8-K","filed_at":"2022-08-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Surgery Partners Q2 revenue up 13.3% to $615.4M; Adj EBITDA up 13.4% to $86.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $615.4M vs $543.3M; net loss $18.4M vs $26.9M in prior year quarter.","Days adjusted same-facility revenues up 6.9%; cases +1.9%, revenue per case +4.9%.","Adj EBITDA ex-CARES grants up 17.8% to $86.0M; margin 14.0%.","2022 guidance reaffirmed: revenue $2.5-2.6B, Adj EBITDA $375-385M.","Deployed ~$90M in six acquisitions at ~7x average multiple; liquidity $227.4M cash plus $203M revolver."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":1211600000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1759100722.2663202,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":372706,"accession_number":"0001638833-22-000102","cik":1638833,"company_name":"Surgery Partners, Inc.","ticker":"SGRY","form_type":"8-K","filed_at":"2022-05-20T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Surgery Partners stockholders re-elect three Class I directors, approve say-on-pay, ratify Deloitte","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["John A. Deane re-elected with 76.4M votes for, 9.7M withheld.","Say-on-pay approved: 84.2M for, 1.8M against, 49K abstentions.","Ratification of Deloitte & Touche as auditor: 87.6M for, 13.3K against.","All proposals passed at May 19, 2022 annual meeting; 89.9M shares outstanding."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":1759100722.2663202,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":372705,"accession_number":"0001638833-22-000094","cik":1638833,"company_name":"Surgery Partners, Inc.","ticker":"SGRY","form_type":"8-K","filed_at":"2022-05-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Surgery Partners Q1 revenue $596.2M (+16.4%), net income $12.2M; raises FY2022 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $596.2M (+16.4% YoY); net income $12.2M vs prior-year net loss $31.3M.","Days adjusted same-facility revenue +8.2%, case volume +6.3% vs prior-year quarter.","Adjusted EBITDA $77.1M (+5.8% YoY); ex-CARES grants $76.1M (+22.3% YoY).","Raised FY2022 guidance: revenue $2.5-2.6B, Adjusted EBITDA $375-385M.","Finalized partnership with ValueHealth; acquired three ASCs and four ortho-focused de novos."],"consensus_eps_estimate":null,"consensus_eps_actual":0.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":596200000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1759100722.2663202,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":391528,"accession_number":"0001638833-22-000017","cik":1638833,"company_name":"Surgery Partners, Inc.","ticker":"SGRY","form_type":"8-K","filed_at":"2022-02-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Surgery Partners Q4 2021 Adj. EBITDA $114.4M, raises 2022 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2021 revenue $610.2M (+11.3% YoY); net loss $0.1M; Adj. EBITDA $114.4M (+26.0%, incl. $11.6M CARES grants).","Full-year 2021 revenue $2.225B (+19.6% YoY); Adj. EBITDA $339.6M (+32.3%, incl. $25.3M CARES grants).","Days adjusted same-facility revenue +9.6% in Q4; case volume +4.2%. Full-year same-facility revenue +18.1%.","2022 guidance: revenue at least $2.5B (+12% YoY); Adj. EBITDA $370-380M, raised from prior outlook.","Cash $389.9M at Dec. 31; total net debt/EBITDA leverage 5.58x; capital deployment target at least $200M annually."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":2225100000.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1759100722.2663202,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":391527,"accession_number":"0001638833-22-000002","cik":1638833,"company_name":"Surgery Partners, Inc.","ticker":"SGRY","form_type":"8-K","filed_at":"2022-01-10T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Surgery Partners reaffirms 2021/2022 guidance, appoints David Doherty as CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["David Doherty appointed EVP & CFO effective Feb 1, 2022, succeeding Thomas Cowhey who resigns Jan 31, 2022.","Doherty receives $515K base salary, 75% target bonus, $200K restricted stock award, $800K annual equity target.","Company reaffirms 2021 Adjusted EBITDA guidance of $325M-$330M and revenue growth 19%-21% vs 2020.","Completed $185M in three December 2021 acquisitions at ~8.5x 2022E EBITDA; reaffirms 2022 Adj EBITDA min $370M.","Cowhey to remain through Feb 2022; his unvested PSUs and restricted stock vest in March 2022 as agreed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1759100722.2663202,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":409727,"accession_number":"0001104659-21-142528","cik":1638833,"company_name":"Surgery Partners, Inc.","ticker":"SGRY","form_type":"8-K","filed_at":"2021-11-22T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Surgery Partners increases revolving credit facility by $40M to $210M","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Seventh Amendment to credit agreement ups aggregate revolving commitments from $170M to $210M.","Amendment dated Nov 19, 2021; Jefferies Finance LLC is administrative and collateral agent.","New $40M incremental revolving commitments rank pari passu with existing revolving loans.","Effectiveness subject to customary conditions: representations, no default, solvency certificate, legal opinion.","Additional capacity supports working capital and general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1759100722.2663202,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":409726,"accession_number":"0001104659-21-136032","cik":1638833,"company_name":"Surgery Partners, Inc.","ticker":"SGRY","form_type":"8-K","filed_at":"2021-11-09T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Surgery Partners prices public offering of 6M shares at $46.50 per share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 6,000,000 common shares at $46.50 each; underwriters granted 30-day option for 900,000 additional shares.","Underwriters include BofA Securities, J.P. Morgan Securities, and Jefferies LLC.","Stock is listed on Nasdaq under ticker SGRY; closing expected on November 12, 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1759100722.2663202,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":409725,"accession_number":"0001638833-21-000144","cik":1638833,"company_name":"Surgery Partners, Inc.","ticker":"SGRY","form_type":"8-K","filed_at":"2021-11-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Surgery Partners Q3 revenue up 12.7% to $559.2M; raises FY EBITDA guidance to $325-330M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $559.2M (+12.7% YoY); net loss $22.9M; adjusted EBITDA $76.4M (+25% YoY).","Same-facility revenue +8.3%, case volume +6.2% vs prior year quarter.","FY 2021 adjusted EBITDA guidance raised to $325M-$330M.","Deployed over $130M on acquisitions YTD; 3 ASCs bought in Aug; $225M under LOI.","Cash $330.4M; revolver capacity $163M; net debt/EBITDA ratio 6.25x."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":1614900000.0,"consensus_period":"2021-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1759100722.2663202,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2021-11-02T23:59:59+00:00|409725"}